Continuous infusion of 5-FU and Leucovorin mixture (LF) for metastatic gastric cancer refractory to prior 5-FU bolus regimen.
- Author:
Hyun Jee KIM
1
;
Young Jin NAM
;
Young Jin YUH
;
Sung Rok KIM
Author Information
1. Department of Internal Medicine, Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Korea. yhyjlove@freechal.com
- Publication Type:Original Article
- Keywords:
Chemotherapy;
Carcinoma;
Stomach;
Leucovorin;
5-fluorouracil
- MeSH:
Agranulocytosis;
Diagnosis;
Drug Therapy;
Fluorouracil*;
Humans;
Leucovorin*;
Leukopenia;
Nausea;
Stomach;
Stomach Neoplasms*;
Stomatitis;
Vomiting
- From:Korean Journal of Medicine
2002;63(2):203-208
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: Most patients with gastric cancer have metastatic disease at first diagnosis and need palliative chemotherapy. Unfortunately, the response duration of the first line chemotherapy is usually short and most patients need the second line therapy during their disease process. The action mechanism of continuous infusion of 5-FU is different from bolus 5-FU and we can expect that among patients who failed on bolus 5-FU, some patients will achieve response to infusional 5-FU. So, we planned to evaluate the efficacy and safety of leucovorin and infusional 5-FU as a second line regimen for the metastatic gastric cancer refractory to regimen containing bolus 5-FU. METHODS: Patients with recurred or metastatic gastric cancer unresponsive to regimen containing bolus 5-FU were entered into this study. The mixture of 5-FU 1,000 mg/m2/day and leucovorin 50 mg/m2/day was infused continuously for four days and this treatment was repeated by every three weeks. RESULTS: From March, 1996 to July 2001, 25 patients were enrolled in this study. One patient showed a partial remission, 9 stable disease and 15 progressive disease. The overall response rate was 4%. The median time to progression was 73 days and the median duration of overall survival was 140 days. Among total of 92 cycle chemotherapy, leukopenia, granulocytopenia and thrombocytopena of WHO grade 3 or 4 were observed in 7.6%, 12.0% and 14.1%, respectively. Stomatitis, nausea or vomiting of WHO grade 3 or 4 were 13.1%, 5.4%, respectively. Neutropenic infection occurred in two patients. CONCLUSION: The LF regimen was well tolerated with minimal toxicities and showed low effect as the second line chemotherapy for the patients with gastric cancer.
